Vimarsana
Biggest News Aggregation in the World

Page 2 - Enzyme Elevations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Enzyme Elevations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Enzyme Elevations Today - Breaking & Trending Today

Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings - Vimarsana News

Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings

Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings Pfizer Inc. announced today that the U.S. Food and Drug Administration has notified the company that it will not meet the Prescription Drug User Fee Act goal dates for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis and the supplemental New Drug Application for XELJANZXELJANZ XR for the treatment of adults with active ankylosing … Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has notified the...

Data Published in New England Journal of Medicine Shows Pfizer's Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia - Vimarsana News

Data Published in New England Journal of Medicine Shows Pfizer's Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% with tofacitinib compared to 29.0% with placebo, in hospitalized patients with COVID-19 pneumonia Multi-center, randomized, double-blind, placebo-controlled trial conducted across 15 sites in Brazil Tofacitinib is not approved or authorized for the treatment of COVID-19 patients. Tofacitinib should not be used in … Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% (26 of 144) with tofacitinib compared to 29.0% (42 of 145) with placebo, in hospitali...

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis - Vimarsana News

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis Pfizer Inc. today announced that the U.S. Food and Drug Administration has extended the priority review period for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis. The Prescription Drug User Fee Act goal date has been extended three months to early Q3 2021. The FDA has also extended the review period for the Supplemental New Drug … Pfizer Inc. (NYSE: PFE) today announced that the...

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for Treatment of Moderate to Severe Atopic Dermatitis - Vimarsana News

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for Treatment of Moderate to Severe Atopic Dermatitis

Date Time Share Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for Treatment of Moderate to Severe Atopic Dermatitis NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has extended the priority review period for the New Drug Application (NDA) for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis. The Prescription Drug User Fee Act (PDUFA) goal date has been extended three months to early Q3 2021. The FDA has also extended the review period for the Su...

Pfizer shares co-primary endpoint results - Vimarsana News

Pfizer shares co-primary endpoint results

1.48 (1.04, 2.09)**** BID=twice daily; CI=confidence interval; HR=hazard ratio; IR=incidence rate; NMSC=non-melanoma skin cancer; TNFi=Tumor Necrosis Factor inhibitor. (*) Based on Cox proportional hazard model (**)The 10 mg BID treatment group includes patients that were switched from 10 mg BID to 5 mg BID as a result of a study modification in February 2019. (***) The risk period included all available follow-up regardless of treatment exposure. (****) The non-inferiority criterion was not met for the primary comparison of the combined tofacitinib doses to TNFi since the upper limit of the ...